Abstract
Background. Direct antiglobulin test (DAT), the hallmark of autoimmune haemolytic anaemia (AIHA), can be performed with different laboratory techniques, which have variable sensitivity and/or specificity. In a minority of patients, named DAT-negative AIHA, the diagnosis is made in exclusion. We recently described a new method for the detection of anti-RBC antibodies in mitogen-stimulated whole blood cultures, named mitogen-stimulated-DAT (MS-DAT). Aim. To investigate the prevalence of MS-DAT positivity in a larger series of DAT-positive and DAT-negative AIHA at different states of disease activity, and in B-CLL with or without DAT-positive AIHA. Materials and methods. We studied 33 DAT-positive AIHA with different disease activity, 7 DAT-negative AIHA, and 69 B-CLL patients. MS-DAT was performed by stimulating whole blood cultures with mitogens, and anti-RBC antibodies were detected by competitive solid phase ELISA. Standard DAT was performed with tube test, in solid phase and with enhancing solutions. Results. MS-DAT was positive in 6 DAT-negative patients with a history of DAT-positive AIHA, who were in clinical and laboratory remission at the moment of the study, and in 7 DAT-negative haemolytic anaemias, diagnosed as autoimmune in exclusion. MS-DAT was positive in 1/3 of the B-CLL patients without haemolytic features. MS-DAT was routinely performed during the follow-up of AIHA patients, and its values correlated with the clinical course, haemolytic parameters and response to therapy. Conclusions. In the test described here mitogen stimulation seems able to disclose a latent anti-RBC autoimmunity, both in AIHA in clinical remission and in B-CLL. MS-DAT could be proposed as an additional test for the diagnosis and monitoring of AIHA, and for the screening of those pathological conditions in which anti-RBC autoimmunity is known to be potentially harmful.
| Original language | Italian |
|---|---|
| Pages (from-to) | 127-136 |
| Number of pages | 10 |
| Journal | Blood Transfusion |
| Volume | 1 |
| Issue number | 2 |
| Publication status | Published - 2003 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Immunology and Allergy
Cite this
Test diretto all’antiglobulina stimolato con mitogeni. / Barcellini, Wilma; Zaninoni, Anna; Imperiali, Francesca Guia; Zanella, Alberto.
In: Blood Transfusion, Vol. 1, No. 2, 2003, p. 127-136.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Test diretto all’antiglobulina stimolato con mitogeni
AU - Barcellini, Wilma
AU - Zaninoni, Anna
AU - Imperiali, Francesca Guia
AU - Zanella, Alberto
PY - 2003
Y1 - 2003
N2 - Background. Direct antiglobulin test (DAT), the hallmark of autoimmune haemolytic anaemia (AIHA), can be performed with different laboratory techniques, which have variable sensitivity and/or specificity. In a minority of patients, named DAT-negative AIHA, the diagnosis is made in exclusion. We recently described a new method for the detection of anti-RBC antibodies in mitogen-stimulated whole blood cultures, named mitogen-stimulated-DAT (MS-DAT). Aim. To investigate the prevalence of MS-DAT positivity in a larger series of DAT-positive and DAT-negative AIHA at different states of disease activity, and in B-CLL with or without DAT-positive AIHA. Materials and methods. We studied 33 DAT-positive AIHA with different disease activity, 7 DAT-negative AIHA, and 69 B-CLL patients. MS-DAT was performed by stimulating whole blood cultures with mitogens, and anti-RBC antibodies were detected by competitive solid phase ELISA. Standard DAT was performed with tube test, in solid phase and with enhancing solutions. Results. MS-DAT was positive in 6 DAT-negative patients with a history of DAT-positive AIHA, who were in clinical and laboratory remission at the moment of the study, and in 7 DAT-negative haemolytic anaemias, diagnosed as autoimmune in exclusion. MS-DAT was positive in 1/3 of the B-CLL patients without haemolytic features. MS-DAT was routinely performed during the follow-up of AIHA patients, and its values correlated with the clinical course, haemolytic parameters and response to therapy. Conclusions. In the test described here mitogen stimulation seems able to disclose a latent anti-RBC autoimmunity, both in AIHA in clinical remission and in B-CLL. MS-DAT could be proposed as an additional test for the diagnosis and monitoring of AIHA, and for the screening of those pathological conditions in which anti-RBC autoimmunity is known to be potentially harmful.
AB - Background. Direct antiglobulin test (DAT), the hallmark of autoimmune haemolytic anaemia (AIHA), can be performed with different laboratory techniques, which have variable sensitivity and/or specificity. In a minority of patients, named DAT-negative AIHA, the diagnosis is made in exclusion. We recently described a new method for the detection of anti-RBC antibodies in mitogen-stimulated whole blood cultures, named mitogen-stimulated-DAT (MS-DAT). Aim. To investigate the prevalence of MS-DAT positivity in a larger series of DAT-positive and DAT-negative AIHA at different states of disease activity, and in B-CLL with or without DAT-positive AIHA. Materials and methods. We studied 33 DAT-positive AIHA with different disease activity, 7 DAT-negative AIHA, and 69 B-CLL patients. MS-DAT was performed by stimulating whole blood cultures with mitogens, and anti-RBC antibodies were detected by competitive solid phase ELISA. Standard DAT was performed with tube test, in solid phase and with enhancing solutions. Results. MS-DAT was positive in 6 DAT-negative patients with a history of DAT-positive AIHA, who were in clinical and laboratory remission at the moment of the study, and in 7 DAT-negative haemolytic anaemias, diagnosed as autoimmune in exclusion. MS-DAT was positive in 1/3 of the B-CLL patients without haemolytic features. MS-DAT was routinely performed during the follow-up of AIHA patients, and its values correlated with the clinical course, haemolytic parameters and response to therapy. Conclusions. In the test described here mitogen stimulation seems able to disclose a latent anti-RBC autoimmunity, both in AIHA in clinical remission and in B-CLL. MS-DAT could be proposed as an additional test for the diagnosis and monitoring of AIHA, and for the screening of those pathological conditions in which anti-RBC autoimmunity is known to be potentially harmful.
KW - AIHA
KW - Autoimmunity
KW - B-CLL
KW - Mitogen-stimulated DAT
UR - http://www.scopus.com/inward/record.url?scp=47749092067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47749092067&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:47749092067
VL - 1
SP - 127
EP - 136
JO - Blood Transfusion
JF - Blood Transfusion
SN - 1723-2007
IS - 2
ER -